Results 1 to 10 of about 982 (100)

Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review

Journal of Endocrinological Investigation, 2018
Insulinomas are a rare type of pancreatic neuroendocrine tumours characterized by insulin hypersecretion. They are considered malignant when metastases are present. Traditional therapies often promote only temporarily symptomatic relief and may be associated with severe adverse effects.
D. Magalhães, I. L. Sampaio, G. Ferreira, P. Bogalho, D. Martins-Branco, R. Santos, H. Duarte   +6 more
openaire   +3 more sources

Hematological Side Effects of 177Lu-DOTA-TATE Therapy in Patients with NENs

Hemato
Background/Objectives: Lutathera® ([177Lu]Lu-DOTA-TATE) is the first radiolabelled somatostatin (SST) analog approved for the treatment of patients with well-differentiated (G1 and G2) unresectable or metastatic gastro-entero-pancreatic neuro-endocrine-neoplasms (GEP-NENs).
Carideo L., Meucci R., Campagna G., Russo V. M., D'Ippolito E., Rinzivillo M., Panzuto F., Prosperi D.   +7 more
openaire   +3 more sources

Interim Results of a Phase I/II Clinical Study to Assess the Safety And Efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-TATE Produced by the N.N. Blokhin National Medical Research Center of Oncology in Patients with Neuroendocrine Neoplasia

Journal of oncology: diagnostic radiology and radiotherapy
Introduction : Peptide-receptor radionuclide therapy (PRRT) is currently a well-studied treatment option for patients with neuroendocrine tumors. Based on the results of the Phase III NETTER-1 and NETTER-2 trials, 177 Lu-DOTA-TATE therapy has become the standard for second-
O. D. Baranova, A. S. Krylov, Yа. A. Zhulikov, E. V. Artamonova, A. A. Markovich, D. V. Likhosherstova, A. V. Filimonov, P. E. Tulin, B. I. Dolgushin, I. S. Stilidi   +9 more
openaire   +1 more source

Safety and kinetic variation profile of 177Lu-DOTA-TATE uptake in Neuroendocrine Tumors

, 2017
Trabalho de Projeto do Mestrado Integrado em Medicina apresentado à Faculdade de ...
openaire   +1 more source

A sstR2-targeted radiohybrid theranostic agent for PET imaging and β^- therapy with excellent preclinical performance. [PDF]

Npj Imaging
Deiser S, Fenzl S, König V, Inoue S, Casini A.   +4 more
europepmc   +1 more source

Improved patient models for simulation of clinically realistic ⁶⁸Ga-SSTR PET and ¹⁷⁷Lu-PRRT SPECT studies. [PDF]

EJNMMI Phys
Gustafsson J, Kalaitzidis P, Curkic Kapidzic S, Ljungberg M, Sjögreen Gleisner K.   +4 more
europepmc   +1 more source

Investigation of iterative deconvolution in ¹⁷⁷Lu-SPECT imaging for lesion dosimetry. [PDF]

EJNMMI Phys
Ells Z, Liubchenko G, Rumiantcev M, Scheifele M, Noto A, Siegmund SC, Resch S, Harbach A, Werner RA, Brendel M, Sheikh G, Zacherl M, Böning G, Unterrainer LM, Ziegler SI, Delker A.   +15 more
europepmc   +1 more source

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE. [PDF]

EJNMMI Res
Liu F, Yang H, Zhang J, Li J, Qiao Y, Chen J, Song S.   +6 more
europepmc   +1 more source

Combination therapy strategies in engineered ¹⁷⁷Lu radiopharmaceuticals beyond single modality: design principles and application outlet. [PDF]

Cell Commun Signal
Zhu Y, Zhong G, Zhang W, Wei W, Yin B, Zhang K.   +5 more
europepmc   +1 more source

[¹⁷⁷Lu]Lu-DOTA-TATE tumour and organ time-activity curves: prediction from a single-time-point [⁶⁸Ga]Ga-DOTA-TATE PET/CT measurement. [PDF]

EJNMMI Phys
Vasić V, Gustafsson J, Yousefzadeh-Nowshahr E, Beer AJ, Sjögreen Gleisner K, Glatting G.   +5 more
europepmc   +1 more source